Sharp earnings and sales growth reported by Lundbeck

8 November 2023

Danish CNS specialist Lundbeck (LUND: CO) today released financials, showing that revenue increased by 10% (+9% constant exchange; CER) to 14,934 million kroner ($2,148.8 million) in the first nine months of 2023, driven mainly by growth in the USA and Europe.

In the USA, sales for the nine months came in at 7,317 million kroner (+11%; +13% CER). In Europe, the figure was 3,454 million kroner (+10%; +11% CER), while in International Markets revenues were 3,926 million kroner (-2%; +3% CER).

Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) increased to 4,859 million euros (+31%; +20% CER) and adjusted EBITDA margin reached 32.5% equivalent to an increase of 5.2 percentage points. Adjusted earnings per share (EPS) reached 3.65 equivalent to an increase of 27%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK